Black Diamond Therapeutics Files 8-K for Regulation FD Disclosure

Ticker: BDTX · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1701541

Black Diamond Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyBlack Diamond Therapeutics, Inc. (BDTX)
Form Type8-K
Filed DateJan 4, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, disclosure, corporate-governance

TL;DR

**BDTX filed an 8-K for general disclosure, keeping investors updated.**

AI Summary

Black Diamond Therapeutics, Inc. filed an 8-K on January 4, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing, which includes their Common Stock ($0.0001 par value per share) traded on The Nasdaq Global Select Market under the symbol BDTX, indicates that the company is providing current information to the public. For investors, this matters because it signals transparency and provides access to potentially new, material information that could influence stock valuation, even if the filing itself doesn't detail a specific event.

Why It Matters

This filing ensures Black Diamond Therapeutics is transparent with investors, providing access to current information that could impact investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure filing and does not inherently present new risks, but rather provides information.

Analyst Insight

A smart investor would review the full contents of the 8-K filing, particularly any exhibits, to understand the specific information being disclosed under Regulation FD and assess its potential impact on the company's outlook or valuation.

Key Numbers

  • $0.0001 — par value per share (the stated par value of Black Diamond Therapeutics' Common Stock)
  • 001-39200 — SEC File Number (Black Diamond Therapeutics' SEC file number)

Key Players & Entities

  • Black Diamond Therapeutics, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Global Select Market (company) — exchange where BDTX Common Stock is registered
  • $0.0001 (dollar_amount) — par value per share of Common Stock
  • January 4, 2024 (date) — date of earliest event reported and filing date
  • BDTX (company) — trading symbol for Black Diamond Therapeutics, Inc.

FAQ

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant as specified in its charter is BLACK DIAMOND THERAPEUTICS, INC.

On what date was the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was January 4, 2024.

What is the trading symbol for Black Diamond Therapeutics, Inc. on the Nasdaq Global Select Market?

The trading symbol for Black Diamond Therapeutics, Inc. on The Nasdaq Global Select Market is BDTX.

What is the par value per share for Black Diamond Therapeutics' Common Stock?

The par value per share for Black Diamond Therapeutics' Common Stock is $0.0001.

Under which items of Form 8-K was this report filed?

This report was filed under ITEM INFORMATION: Regulation FD Disclosure and ITEM INFORMATION: Financial Statements and Exhibits.

Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-01-04 08:07:08

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share BDTX The Nasdaq G

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 4, 2024, Black Diamond Therapeutics, Inc. (the " Company ") issued a press release titled, " Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones " and updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the press release and a copy of the corporate presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on the Form 8-K. The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Black Diamond Therapeutics, Inc., dated January 4, 2024. 99.2 Corporate Presentation of Black Diamond Therapeutics, Inc. as of January 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BLACK DIAMOND THERAPEUTICS, INC. Date: January 4, 2024 By: /s/ Brent Hatzis-Schoch Name: Brent Hatzis-Schoch Title: Chief Operating Officer and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.